Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Exelixis
Sponsor:
Information provided by (Responsible Party):
Exelixis
ClinicalTrials.gov Identifier:
NCT01908426
First received: July 23, 2013
Last updated: August 4, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)